NEUSTAR
27.7.2021 09:39:11 CEST | Business Wire | Press release
Neustar Inc. , a global information services and technology company and leader in identity resolution, today introduced UltraBot Protect to provide users with more visibility into, and control over, their application layer traffic. UltraBot Protect delivers enhanced capabilities that allow users to examine traffic patterns to determine risk, easily set rules, and block nefarious web application traffic, all through an intuitive, dynamic and comprehensive user interface or Neustar’s extensible API, both of which deliver actionable data and insights to better manage incoming traffic.
Neustar’s portfolio of application security products, which also includes UltraDDoS Protect and UltraWAF , utilises deep insights of network traffic to ensure users’ digital networks are secure across all touchpoints. Newly augmented with the robust bot management capabilities of UltraBot Protect, it becomes even more powerful.
“As digital initiatives accelerated during the pandemic, companies invested in application-rich environments that have inadvertently created opportunity for bad actors,” said Michael Kaczmarek, vice president of product management for Neustar’s Security Solutions business. “Cybercriminals are exploiting security gaps – such as through automated scanning that provides broad coverage searching for certain vulnerabilities in applications and infrastructure solutions – to find and attack new targets, especially in industries like gaming, retail and e-commerce, healthcare, and financial services.”
A recent Neustar International Security Council (NISC) report found that 84% of organisations invest significant time into continually modifying their web application firewalls (WAFs) to keep up with ever-growing, increasingly stealthy application-layer attacks. Even for organisations that have a highly tuned and optimised WAF on premises, the sheer volume of traffic and potential threats can exhaust resources and impact the ability to introduce greater precision to key systems.
Added Kaczmarek: “The rapid evolution of the modern enterprise has created precarious interdependencies and security gaps, making it significantly easier to exploit vulnerabilities, especially at the application layer. UltraBot Protect marries extensive bot detection capabilities with a sleek and straightforward interface that gives users a clear and complete view of the data, helping them set effective parameters in managing and blocking traffic to keep systems safe and assets protected.”
UltraBot Protect and all its features are now accessible to UltraWAF and UltraDDoS Protect customers. Features include IP reputation coverage, which involves the review of a wide range of IP categories — scanners, DOS, phishing, proxy, etc. — to examine whether a malicious IP address is the source; device fingerprint, which detects a fingerprint ID in the incoming request header and browser attributes; and bot trap, which determines whether a bot or human user is incoming based on detection traced to a specific bot trap URL. Additionally, UltraBot Protect covers the basics, such as customised block and allow lists, bot rate limits and transactions per second, as well as captcha to detect whether traffic is human or bot generated. More information about UltraBot Protect can be found at https://www.home.neustar/bot-management .
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005468/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
